| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Paeonol (also known as NSC-401442; NSC401442; Peonol), a naturally occurring phenolic compound isolated from Paeonia suffruticosa (moutan cortex) and Cynanchum paniculatum which are used in traditional Chinese herbs/medicines. Paeonol has a range of pharmacologic functions such as antiaggregatory,anti-inflammatory and anti-ischemia reperfusion damage and anti-lipid peroxidation effects. It acts as a MAO inhibitor with an IC50 of about 50 μM.
| ln Vitro |
It is discovered that pedonol inhibits MAO A in a dose-dependent manner, with an IC50 value of 54.6 μM. With an IC50 of 42.5 μM, eonol is demonstrated to inhibit MAO-B in a dose-dependent way. The calculated Ki for Paeonol is 51.1 μM. With a Ki value of 38.2 μM, Paeonol's inhibition of MAO B is of the competitive type[1].
|
||
|---|---|---|---|
| ln Vivo |
When compared to the I/R group [AN/V (%): 18.2±2.9], the 200 mg/kg Paeonol+I/R group [AN/V (%): 7.6±2.2, p<0.01] and the 100 mg/kg Paeonol+I/R group [AN/V (%): 9.4±2.8, p<0.05] both exhibit reduced amounts of no-reflow area in the ventricles. Specifically, compared to the I/R group [AN/WH (%): 10.0±1.9][2], the 200 mg/kg Paeonol + I/R group showed significantly lessened no-reflow in the whole heart [AN/WH (%): 4.6±1, p<0.05].
|
||
| Animal Protocol |
|
||
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Paeonol has known human metabolites that include (2-Acetyl-5-methoxyphenyl) hydrogen sulfate. |
||
| References | |||
| Additional Infomation |
Paeonol is a member of phenols and a member of methoxybenzenes. It has a role as a metabolite.
Paeonol has been reported in Clausena dunniana, Ficus benghalensis, and other organisms with data available. See also: Paeonia lactiflora root (part of); Paeonia X suffruticosa root (part of). |
| Molecular Formula |
C9H10O3
|
|
|---|---|---|
| Molecular Weight |
166.17
|
|
| Exact Mass |
166.062
|
|
| CAS # |
552-41-0
|
|
| Related CAS # |
Paeonol-d3;55712-78-2
|
|
| PubChem CID |
11092
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
301.9±22.0 °C at 760 mmHg
|
|
| Melting Point |
48-50 °C(lit.)
|
|
| Flash Point |
122.3±15.8 °C
|
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
|
| Index of Refraction |
1.538
|
|
| LogP |
2.16
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
12
|
|
| Complexity |
167
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
UILPJVPSNHJFIK-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C9H10O3/c1-6(10)8-4-3-7(12-2)5-9(8)11/h3-5,11H,1-2H3
|
|
| Chemical Name |
1-(2-Hydroxy-4-methoxyphenyl)ethanone
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: 10% EtOH + 90% Corn Oil |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0179 mL | 30.0897 mL | 60.1793 mL | |
| 5 mM | 1.2036 mL | 6.0179 mL | 12.0359 mL | |
| 10 mM | 0.6018 mL | 3.0090 mL | 6.0179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04657926 | Completed | Drug: APPA Drug: Placebo |
Osteoarthritis | AKL Research and Development | September 9, 2020 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
